Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
暂无分享,去创建一个
G. Hortobagyi | F. André | M. Campone | L. Hart | C. Arteaga | Y. Yap | D. Yardley | E. Alba | E. Grischke | S. Paluch-Shimon | G. Sonke | K. Petráková | S. Tolaney | A. Chan | Wei He | E. Jakobsen | S. Blau | C. Germa | C. Villanueva | A. Nusch | S. Stemmer | N. Marschner | F. Su